{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:47:24Z","timestamp":1777420044233,"version":"3.51.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12967-015-0678-7","type":"journal-article","created":{"date-parts":[[2015,9,30]],"date-time":"2015-09-30T00:18:31Z","timestamp":1443572311000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma"],"prefix":"10.1186","volume":"13","author":[{"given":"Ahmad A.","family":"Tarhini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haris","family":"Zahoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer H.","family":"Yearley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Dubner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uma N. M.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy","family":"Sander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Kirkwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,9,30]]},"reference":[{"issue":"7","key":"678_CR1","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027\u201334.","journal-title":"J Exp Med"},{"issue":"19","key":"678_CR2","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"99","author":"Y Iwai","year":"2002","unstructured":"Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA. 2002;99(19):12293\u20137. doi: 10.1073\/pnas.192461099 .","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"678_CR3","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.4049\/jimmunol.0803648","volume":"182","author":"VV Parekh","year":"2009","unstructured":"Parekh VV, Lalani S, Kim S, Halder R, Azuma M, Yagita H, et al. PD-1\/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells. J Immunol. 2009;182(5):2816\u201326. doi: 10.4049\/jimmunol.0803648 .","journal-title":"J Immunol."},{"issue":"8","key":"678_CR4","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1073\/pnas.0813367106","volume":"106","author":"O Talay","year":"2009","unstructured":"Talay O, Shen CH, Chen L, Chen J. B7-H1 (PD-L1) on T cells is required for T-cell-mediated conditioning of dendritic cell maturation. Proc Natl Acad Sci USA. 2009;106(8):2741\u20136. doi: 10.1073\/pnas.0813367106 .","journal-title":"Proc Natl Acad Sci USA"},{"issue":"27","key":"678_CR5","doi-asserted-by":"crossref","first-page":"9331","DOI":"10.1073\/pnas.0710441105","volume":"105","author":"L Wang","year":"2008","unstructured":"Wang L, Pino-Lagos K, de Vries VC, Guleria I, Sayegh MH, Noelle RJ. Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+regulatory T cells. Proc Natl Acad Sci USA. 2008;105(27):9331\u20136. doi: 10.1073\/pnas.0710441105 .","journal-title":"Proc Natl Acad Sci USA"},{"key":"678_CR6","author":"MA Postow","year":"2015","unstructured":"Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clinl Oncol Off J Am Soc Clin Oncol. 2015;. doi: 10.1200\/JCO.2014.59.4358 .","journal-title":"J Clinl Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"678_CR7","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.critrevonc.2013.08.002","volume":"89","author":"B Merelli","year":"2014","unstructured":"Merelli B, Massi D, Cattaneo L, Mandala M. Targeting the PD1\/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities. Crit Rev Oncol\/Hematol. 2014;89(1):140\u201365. doi: 10.1016\/j.critrevonc.2013.08.002 .","journal-title":"Crit Rev Oncol\/Hematol."},{"issue":"49","key":"678_CR8","doi-asserted-by":"crossref","first-page":"17174","DOI":"10.1073\/pnas.0406351101","volume":"101","author":"RH Thompson","year":"2004","unstructured":"Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA. 2004;101(49):17174\u20139. doi: 10.1073\/pnas.0406351101 .","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"678_CR9","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0611533104","volume":"104","author":"J Hamanishi","year":"2007","unstructured":"Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA. 2007;104(9):3360\u20135. doi: 10.1073\/pnas.0611533104 .","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"678_CR10","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/cncr.22588","volume":"109","author":"BA Inman","year":"2007","unstructured":"Inman BA, Sebo TJ, Frigola X, Dong H, Bergstralh EJ, Frank I, et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer. 2007;109(8):1499\u2013505. doi: 10.1002\/cncr.22588 .","journal-title":"Cancer"},{"issue":"8","key":"678_CR11","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00262-006-0266-z","volume":"56","author":"J Nakanishi","year":"2007","unstructured":"Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K, Ueda S. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother CII. 2007;56(8):1173\u201382. doi: 10.1007\/s00262-006-0266-z .","journal-title":"Cancer Immunol Immunother CII"},{"issue":"7","key":"678_CR12","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1158\/1078-0432.CCR-06-2746","volume":"13","author":"T Nomi","year":"2007","unstructured":"Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand\/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2007;13(7):2151\u20137. doi: 10.1158\/1078-0432.CCR-06-2746 .","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"5","key":"678_CR13","first-page":"458","volume":"10","author":"JM Zhao","year":"2007","unstructured":"Zhao JM, Wu CP, Wang RC, Xu J, Zhu J, Wei J, et al. Expression and clinical significance of costimulatory molecule B7-H3 mRNA and B7-H3 protein in gastric carcinoma. Zhonghua wei chang wai ke za zhi\u00a0=\u00a0Chin J Gastrointest Surg. 2007;10(5):458\u201362.","journal-title":"Zhonghua wei chang wai ke za zhi = Chin J Gastrointest Surg"},{"issue":"3","key":"678_CR14","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.4049\/jimmunol.170.3.1257","volume":"170","author":"JA Brown","year":"2003","unstructured":"Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol. 2003;170(3):1257\u201366.","journal-title":"J Immunol"},{"issue":"8","key":"678_CR15","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793\u2013800. doi: 10.1038\/nm730 .","journal-title":"Nat Med"},{"issue":"15","key":"678_CR16","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1158\/1078-0432.CCR-04-0428","volume":"10","author":"J Konishi","year":"2004","unstructured":"Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res Off J Am Assoc Cancer Res. 2004;10(15):5094\u2013100. doi: 10.1158\/1078-0432.CCR-04-0428 .","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"10","key":"678_CR17","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1002\/cncr.21470","volume":"104","author":"RH Thompson","year":"2005","unstructured":"Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, et al. Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer. 2005;104(10):2084\u201391. doi: 10.1002\/cncr.21470 .","journal-title":"Cancer"},{"issue":"7","key":"678_CR18","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1158\/0008-5472.CAN-05-4303","volume":"66","author":"RH Thompson","year":"2006","unstructured":"Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006;66(7):3381\u20135. doi: 10.1158\/0008-5472.can-05-4303 .","journal-title":"Cancer Res"},{"issue":"3","key":"678_CR19","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/0008-5472.1089.65.3","volume":"65","author":"F Hirano","year":"2005","unstructured":"Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005;65(3):1089\u201396 (65\/3\/1089 [pii]).","journal-title":"Cancer Res"},{"issue":"7","key":"678_CR20","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1182\/blood-2007-11-123141","volume":"111","author":"T Azuma","year":"2008","unstructured":"Azuma T, Yao S, Zhu G, Flies AS, Flies SJ, Chen L. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood. 2008;111(7):3635\u201343. doi: 10.1182\/blood-2007-11-123141 .","journal-title":"Blood"},{"issue":"18","key":"678_CR21","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1074\/jbc.M709493200","volume":"283","author":"AJ Ramsay","year":"2008","unstructured":"Ramsay AJ, Dong Y, Hunt ML, Linn M, Samaratunga H, Clements JA, et al. Kallikrein-related peptidase 4 (KLK4) initiates intracellular signaling via protease-activated receptors (PARs). KLK4 and PAR-2 are co-expressed during prostate cancer progression. J Biol Chem. 2008;283(18):12293\u2013304. doi: 10.1074\/jbc.M709493200 .","journal-title":"J Biol Chem"},{"key":"678_CR22","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1146\/annurev.immunol.23.021704.115611","volume":"23","author":"RJ Greenwald","year":"2005","unstructured":"Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23:515\u201348. doi: 10.1146\/annurev.immunol.23.021704.115611 .","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"678_CR23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.it.2006.02.001","volume":"27","author":"T Okazaki","year":"2006","unstructured":"Okazaki T, Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol. 2006;27(4):195\u2013201. doi: 10.1016\/j.it.2006.02.001 .","journal-title":"Trends Immunol"},{"key":"678_CR24","doi-asserted-by":"crossref","unstructured":"Fourcade J, Kudela P, Sun Z, Shen H, Land SR, Lenzner D, et al. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol (Baltim Md 1950). 2009;182(9):5240\u20139. doi: 10.4049\/jimmunol.0803245 .","DOI":"10.4049\/jimmunol.0803245"},{"issue":"19","key":"678_CR25","first-page":"6501","volume":"63","author":"SE Strome","year":"2003","unstructured":"Strome SE, Dong H, Tamura H, Voss SG, Flies DB, Tamada K, et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 2003;63(19):6501\u20135.","journal-title":"Cancer Res"},{"issue":"7","key":"678_CR26","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/cncr.24899","volume":"116","author":"R Hino","year":"2010","unstructured":"Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer. 2010;116(7):1757\u201366. doi: 10.1002\/cncr.24899 .","journal-title":"Cancer"},{"issue":"9948","key":"678_CR27","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","volume":"384","author":"C Robert","year":"2014","unstructured":"Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109\u201317. doi: 10.1016\/S0140-6736(14)60958-2 .","journal-title":"Lancet"},{"key":"678_CR28","doi-asserted-by":"crossref","unstructured":"Ribas A, Hodi FS, Kefford R, editors. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). In: 50th annual meeting of the American society of clinical oncology; 2014.","DOI":"10.1200\/jco.2014.32.15_suppl.lba9000"},{"key":"678_CR29","doi-asserted-by":"crossref","unstructured":"Kefford R, Ribas A, Hamid O, editors. Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. In: 50th annual meeting of the American society of clinical oncology, Chicago; 2014.","DOI":"10.1200\/jco.2014.32.15_suppl.3005"},{"issue":"1","key":"678_CR30","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0022-3565(24)36594-2","volume":"281","author":"FI Raynaud","year":"1997","unstructured":"Raynaud FI, Orr RM, Goddard PM, Lacey HA, Lancashire H, Judson IR, et al. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice. J Pharmacol Exp Ther. 1997;281(1):420\u20137.","journal-title":"J Pharmacol Exp Ther"},{"key":"678_CR31","doi-asserted-by":"crossref","unstructured":"Weber JS MD, D\u2019Angelo SP, et al. A phase 3 randomized, open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator\u2019s choice chemotherapy (ICC) in patients with advanced melanoma after prior anti-CTLA-4 therapy. In: Program and abstracts from the 39th European society for medical oncology congress, Madrid; 2014. (Abstract LBA3_PR).","DOI":"10.1093\/annonc\/mdu438.34"},{"issue":"4","key":"678_CR32","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320\u201330. doi: 10.1056\/NEJMoa1412082 .","journal-title":"N Engl J Med"},{"issue":"7528","key":"678_CR33","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568\u201371. doi: 10.1038\/nature13954 .","journal-title":"Nature"},{"key":"678_CR34","doi-asserted-by":"crossref","unstructured":"Kefford RRA, Hamid O, et al. Clinical efficacy and correlation with tumor PD-L1 expression in patients with melanoma treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475). In: The 2014 ASCO annual meeting; 2014.","DOI":"10.1200\/jco.2014.32.15_suppl.3005"},{"issue":"16","key":"678_CR35","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2001.19.16.3635","volume":"19","author":"CM Balch","year":"2001","unstructured":"Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19(16):3635\u201348.","journal-title":"J Clin Oncol"},{"key":"678_CR36","doi-asserted-by":"crossref","unstructured":"Balch CM, Soong SJ, Murad TM, Ingalls AL, Maddox WA. A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg. 1981;193(3):377\u201388.","DOI":"10.1097\/00000658-198103000-00023"},{"issue":"16","key":"678_CR37","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1200\/JCO.2001.19.16.3622","volume":"19","author":"CM Balch","year":"2001","unstructured":"Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol Off J Am Soc Clin Oncol. 2001;19(16):3622\u201334.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"36","key":"678_CR38","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(36):6199\u2013206. doi: 10.1200\/JCO.2009.23.4799 .","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"3","key":"678_CR39","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.hoc.2014.02.004","volume":"28","author":"AA Tarhini","year":"2014","unstructured":"Tarhini AA, Thalanayar PM. Melanoma adjuvant therapy. Hematol Oncol Clin N Am. 2014;28(3):471\u201389. doi: 10.1016\/j.hoc.2014.02.004 .","journal-title":"Hematol Oncol Clin N Am"},{"issue":"26","key":"678_CR40","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443\u201354. doi: 10.1056\/NEJMoa1200690 .","journal-title":"N Engl J Med."},{"issue":"34","key":"678_CR41","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2013.51.4802","volume":"31","author":"JS Weber","year":"2013","unstructured":"Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(34):4311\u20138. doi: 10.1200\/JCO.2013.51.4802 .","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"21","key":"678_CR42","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018\u201328. doi: 10.1056\/NEJMoa1501824 .","journal-title":"N Engl J Med."},{"key":"678_CR43","doi-asserted-by":"crossref","unstructured":"Hodi FSSM, Kluger HM, et al. Long-term survival of ipilimumab-na\u00efve patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in a phase I trial. In: The 2014 ASCO annual meeting; 2014.","DOI":"10.1200\/jco.2014.32.15_suppl.9002"},{"key":"678_CR44","doi-asserted-by":"crossref","unstructured":"Gettinger SSF, Antonia SJ, et al. First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced non-small cell lung cancer (NSCLC): safety, efficacy, and correlation of outcomes with PD-L1 status. In: The 2014 ASCO annual meeting; 2014.","DOI":"10.1200\/jco.2014.32.15_suppl.8024"},{"issue":"1","key":"678_CR45","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1158\/0008-5472.CAN-05-2429","volume":"66","author":"JM Roda","year":"2006","unstructured":"Roda JM, Parihar R, Magro C, Nuovo GJ, Tridandapani S, Carson WE 3rd. Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells. Cancer Res. 2006;66(1):517\u201326. doi: 10.1158\/0008-5472.CAN-05-2429 .","journal-title":"Cancer Res"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-015-0678-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T21:28:15Z","timestamp":1748640495000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.translational-medicine.com\/content\/13\/1\/319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,30]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["678"],"URL":"https:\/\/doi.org\/10.1186\/s12967-015-0678-7","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,30]]},"article-number":"319"}}